Health Status Impairments in Tyrosine Kinase Inhibitor-Treated Chronic Myeloid Leukemia Patients Compared with Blood or Marrow Transplant Survivors and Non-Cancer Controls: A Clinical Review

Health Status Impairments in Tyrosine Kinase Inhibitor-Treated Chronic Myeloid Leukemia Patients Compared with Blood or Marrow Transplant Survivors and Non-Cancer Controls: A Clinical Review

This review synthesizes evidence on health status impairments in long-term TKI-treated CML survivors relative to BMT survivors and non-cancer controls, emphasizing rates of functional impairment, activity limitation, frailty, and quality of life impacts, highlighting the necessity for vigilant survivorship care.